IPP-PSP Block vs. SPSIPB in Breast Surgery

November 17, 2025 updated by: Çağdaş Baytar, Zonguldak Bulent Ecevit University

Interpectoral-pectoserratus Plane Block vs. Serratus Posterior Superior Intercostal Plane Block for Postoperative Analgesia in Patients Undergoing Breast Cancer Surgery

This prospective, randomized clinical study aims to compare the analgesic efficacy of the interpectoral-pectoserratus plane block and the serratus posterior superior intercostal plane block for postoperative pain management in patients undergoing breast cancer surgery. Both techniques are ultrasound-guided regional anesthesia methods targeting different interfascial planes of the thoracic wall. The study will evaluate postoperative pain scores, opioid consumption, Quality of recovery and potential complications. The findings are expected to contribute to optimizing regional anesthesia strategies for enhanced recovery and improved analgesia following breast cancer surgery.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

70

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • 18-65 years of age
  • ASA I-II-III risk groups
  • Patients with informed consent
  • Patients undergoing breast cancer surgery

Exclusion Criteria: • Ages <18 and >65

  • ASA ≥ IV
  • History of allergy to local anesthetics
  • Known coagulation disorders
  • Infection near the insertion site
  • Chronic analgesic use
  • Patients with diabetes mellitus and those receiving neoadjuvant chemotherapy (due to potential impairment of pain sensation)
  • Body mass index >30
  • Dementia or confusion
  • Lack of cooperation

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Group IPP-PSP
Interpectoral-Pectoserratus Plane Block
Procedure: Interpectoral-Pectoserratus Plane Block
Ultrasound-guided injection between pectoralis major-minor and pectoralis minor-serratus anterior planes.
Active Comparator: Group SPSIPB
Serratus Posterior Superior Intercostal Plane Block
Procedure: Serratus Posterior Superior Intercostal Plane Block
Ultrasound-guided injection between the serratus posterior superior muscle and the intercostal muscles.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Cumulative opioid consumption
Time Frame: in the first 24 hours after completion of the surgical procedure
Cumulative opioid consumption in the first 24 postoperative hours after the completion of the surgical procedure
in the first 24 hours after completion of the surgical procedure

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Postsurgical Quality of Recovery measured by the Quality of Recovery questionnaire
Time Frame: first day after surgery

Postsurgical recovery by Quality of Recovery questionnaire (QoR-15) on first (D1) day after surgery.

The minimum score on the Quality of Recovery questionnaire is 0 and the maximum score 150. Higher scores mean better quality of recovery.
first day after surgery
Number of episodes of postoperative pain
Time Frame: In the first 24 hours after completion of the surgical procedure
Number of episodes of postoperative pain (NRS score ≥ 4) at rest and at deep inspiration in the first 24 postoperative hours after the completion of the surgical procedure
In the first 24 hours after completion of the surgical procedure

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Zonguldak Bulent Ecevit University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

November 15, 2025

Primary Completion (Estimated)

May 31, 2026

Study Completion (Estimated)

June 30, 2026

Study Registration Dates

First Submitted

November 17, 2025

First Submitted That Met QC Criteria

November 17, 2025

First Posted (Actual)

November 24, 2025

Study Record Updates

Last Update Posted (Actual)

November 24, 2025

Last Update Submitted That Met QC Criteria

November 17, 2025

Last Verified

November 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2025/16-9

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Breast Cancer

Clinical Trials on Interpectoral-Pectoserratus Plane Block

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Suriname

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe